The MedTech world never sleeps, and neither should your inbox. This week: a cyberattack hit one of the biggest names in surgical equipment and is now confirmed as a geopolitically motivated wiper attack. A Dutch blood-draw startup just closed a massive Series B round. A novel BPH implant that removes itself after doing its job just got FDA cleared. And deal talks are heating up at the $9.9 billion level. Welcome to Issue #5 of The MedTech Minute. Let's get into it.
Top Stories
Story 01
Stryker Corporation is working to restore full operations after confirming a destructive cyberattack that wiped data from its Microsoft-based IT systems. The company says it believes the attack has been contained and is now bringing systems back online. Order processing, manufacturing, and shipping were disrupted across multiple divisions. The attack, attributed to an Iranian-backed hacktivist group, is a stark reminder that MedTech manufacturers are high-value targets, ransomware groups know that downtime in this industry means lives, not just revenue.
Why This Matters
Recovery speed reveals how well a company prepared. The fact that Stryker is bringing systems back online within days suggests mature backup protocols, but supply chain disruption is already rippling to hospital purchasing departments. For the industry: a single cyberattack affecting one tier-1 OEM is enough to trigger procurement freezes across entire health systems.
Cybersecurity
Operations
Story 02
Intuitive Surgical disclosed a targeted phishing attack aimed at employees with access to sensitive R&D systems. The maker of the da Vinci surgical robot says no proprietary system data was compromised, but the attack raises red flags about social engineering threats across MedTech. Two major surgical companies hit in the same week is not a coincidence. When threat actors see MedTech as a target category, the entire industry needs to treat security as a patient safety issue, not just an IT problem.
Cybersecurity
Surgical Robotics
Story 03
Dutch autonomous blood-draw startup Vitestro announced a $70 million Series B to accelerate FDA submission and U.S. commercialization of its robot-assisted venipuncture system. The device has already completed over 100,000 draws in Europe. If cleared, it would be the first fully autonomous IV-access robot on the U.S. market, addressing one of the most common causes of patient discomfort, failed draws, and staff injury in clinical settings.
$70M Series B
FDA Pathway
Robotics
Story 04
Prodeon Medical received FDA 510(k) clearance on March 16 for the Urocross Expander System, a non-permanent, retrievable nitinol implant for treating lower urinary tract symptoms caused by an enlarged prostate (BPH). (Source: GlobeNewswire, March 16, 2026) The device is placed transurethrally via cystoscope and gently remodels the prostatic tissue over six months, then it's retrieved, leaving no permanent foreign material behind. That's the key differentiator: existing BPH devices like UroLift leave a permanent implant in place; Urocross removes itself after doing its job. With BPH affecting an estimated 50% of men over 50 (Source: American Urological Association) and surgical options carrying meaningful risk profiles, a retrievable outpatient option could be a significant addition to the urologist's toolkit.
FDA 510(k)
Urology
Know someone in MedTech? Forward this to a colleague. It only takes 5 minutes and saves them from missing the week’s biggest moves.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $512.75 | ▼ 1.8% |
| SYK | Stryker | $348.20 | ▼ 2.4% |
| BDX | BD (Becton Dickinson) | $230.90 | ▲ 0.5% |
| JNJ | Johnson & Johnson | $159.20 | ▲ 0.8% |
| ABT | Abbott | $138.60 | ▼ 0.6% |
| ZBH | Zimmer Biomet | $107.80 | ▲ 0.6% |
| BSX | Boston Scientific | $102.15 | ▲ 1.2% |
| GEHC | GE HealthCare | $91.40 | ▼ 0.8% |
| MDT | Medtronic | $86.40 | ▲ 0.9% |
| EW ★ | Edwards Lifesciences | $72.40 | ▲ 2.3% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 16, 2026.
Deep Dive
The Cyberattack Threat in MedTech Is Escalating, Here’s What to Watch
The Stryker and Intuitive incidents this week are no accident. They’re part of a broader escalation in which ransomware groups and nation-state actors are specifically targeting MedTech companies. The reason is straightforward: high-value IP (surgical robotics, AI diagnostics) combined with the pressure to pay fast when patient care is at risk.
Three things every MedTech operator, investor, and clinician should be tracking:
- FDA cybersecurity guidance is now mandatory for new device submissions. Manufacturers must submit a Software Bill of Materials, a complete inventory of every software component in the device, and a plan for ongoing security patches as part of premarket review. Devices missing this documentation face rejection. Read FDA’s cybersecurity guidance updates.
- Connected devices are the new attack surface. Insulin pumps, pacemakers, implantable defibrillators, and surgical robots all communicate over hospital networks. Each connection is a potential entry point for hackers. The average hospital has 10+ connected devices per bed, up from just 2 in 2015, according to healthcare cybersecurity research (Source: Claroty 2024 Healthcare Cybersecurity Report). That growth means hospitals now have 5 times as many potential entry points for hackers compared to a decade ago.
- M&A due diligence now includes a cybersecurity audit. Acquirers are increasingly discovering legacy security vulnerabilities in acquisition targets. The Danaher–Masimo deal talks are a perfect example, a $9.9B acquisition where security posture will be scrutinized as closely as the revenue model. See MassDevice’s analysis of the Stryker attack implications.
Bottom line: Cybersecurity in MedTech isn’t an IT problem anymore. It’s a regulatory, commercial, and patient safety issue, and the companies that treat it as such will have a clear advantage in the next three years.
Industry Shifts
Shift 01
Sources familiar with the matter indicate Danaher Corporation is in advanced discussions to acquire Masimo, the patient monitoring and signal processing giant, in a deal valued near $9.9 billion. If confirmed, it would rank among the largest MedTech acquisitions of 2026, and signal Danaher’s continued push into high-margin diagnostics and monitoring platforms used in hospital ICUs and operating rooms.
M&A
$9.9B
Shift 02
Medtronic received FDA clearance for its Stealth AXiS robotic-assisted spinal surgery system, expanding its surgical robotics portfolio as competition from Globus Medical, Stryker Mako, and others intensifies. The spinal robotics race is heating up, and Medtronic’s clearance keeps it in a competitive battle for operating room real estate in spine surgery alongside its Hugo system in soft-tissue procedures.
FDA Clearance
Surgical Robotics
Fun Fact & Trivia
Fun Fact
The average hospital now has over 10 connected medical devices per patient bed, up from just 2 in 2015, according to healthcare cybersecurity research. (Source: Claroty 2024 Healthcare Cybersecurity Report) That's 5 times as many connected entry points per bed as a decade ago, and it's a big reason why hospital networks have become prime targets for cyberattacks. Each connected device is a door that has to be locked, monitored, and patched on an ongoing basis.
MedTech Trivia
Which company invented the first commercially successful cardiac pacemaker?
👇 Scroll to the footer for the answer
Sponsor
